Skip to main content

Table 1 Patient characteristics and sub-volume data

From: Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study

Dog no. Tumor type Tumor localization GTV (ccm) FDG40 (ccm) FDG50 (ccm) Cu3 (ccm) Cu24 (ccm) Cu3FDG40 (ccm) Cu3FDG50(ccm) Cu3∩FDG40/FDG40 (%) Cu3∩FDG40/Cu3 (%) Cu3∩FDG50/FDG50 (%) Cu3∩FDG50/Cu3 (%)
1 Hemangiopericytoma Lumbar region 128.7 13.0 3.4 85.8 61.6 86.1 85.9 98.5 14.9 98.2 3.9
2 Fibrosarcoma Lat. cervical region 88.2 66.4 60.1 63.9 17.0 73.9 71.3 84.7 88.4 88.2 82.8
3 Squamous cell carcinoma Nasal cavity 55.4 23.7 17.0 21.2 30.0 28.7 25.4 68.9 76.9 76.4 61.0
4 Adenocarcinoma Nasopharynx 20.8 10.3 5.3 9.3 3.5 13.0 10.7 62.9 69.3 75.4 42.8
5 Undiff. soft tissue sarcoma Mandible 23.2 11.2 8.4 6.2 0.6 12.2 10.2 46.6 83.9 52.8 70.8
Avg.    63.3 24.9 18.8 37.3 22.5 42.8 40.7 72.3 66.7 78.2 52.3